Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis

Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.

A clinical-stage gene therapy company, Atsena Therapeutics focuses on treating rare eye diseases with ocular gene therapy, finding new ways to treat complicated diseases. The company was co-founded by Dr. Shannon E. Boye and Dr. Sanford Boye, researchers at the University of Florida. Dr. Shannon E. Boye runs the Shannon E. Boye laboratory, which specializes in optical gene therapy. Dr. Sanford Boye helps oversee the UF Powell Gene Therapy Center, which is working on research that tackles a variety of genetic diseases.

Dr. Shannon E. Boye was recently recognized as Innovator of the Year at Standing InnOvation 2023 for her work in this field.

Read more about Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis.